GLP-1 receptor agonists and conscious sedation

This FactFinder presents a brief summary of the evidence and outlines recommendations regarding periprocedural management of patients on glucagon-like peptide-1 receptor agonists (GLP-1RA) therapy undergoing elective pain procedures under conscious sedation. Based on current multi-society guidance statements, patients without risk factors may continue GLP-1RA therapy in the periprocedural window. However, periprocedural management should incorporate a complete risk assessment and shared decision-making involving the patient, the prescribing care team, the physician, and anesthesia personnel (if involved). It is also recommended that the performing physician carefully consider the necessity of conscious sedation on a case-by-case basis, as it is not necessary in most scenarios. Myth: All patients on glucagon-like peptide-1 receptor agonists (GLP-1RA) therapy undergoing elective pain procedures under conscious sedation are required to withhold the medication for a set timeframe before the procedure. Fact: Based on current multi-society guidance statements, patients without risk factors may continue GLP-1RA therapy in the periprocedural window. However, periprocedural management should incorporate a complete risk assessment and shared decision-making involving the patient, the prescribing care team, the physician, and anesthesia personnel (if involved). It is also recommended that the performing physician carefully consider the necessity of conscious sedation on a case-by-case basis, as it is not necessary in most scenarios.